Clinical Trial Update: The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of lucinactant inhalation in premature neonates (26-32 weeks gestation) with Respiratory Distress Synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Lucinactant (lucinactant)

Snippet

Sponsor: Windtree Therapeutics | Conditions: Respiratory Distress Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-04-23